LT-1001 is under clinical development by Lumosa Therapeutics and currently in Phase I for Post-Operative Pain. According to GlobalData, Phase I drugs for Post-Operative Pain have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LT-1001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LT-1001 overview
LT-1001 is under development for the treatment of moderate to severe post-operative pain. The drug candidate is a seven days long-acting prodrug of dinalbuphine sebacate, a prodrug of nalbuphine that is administered through intramuscular route. It acts by targeting opioid kappa and opioid mu receptors.
See Also:
Lumosa Therapeutics overview
Lumosa Therapeutics (Lumosa Therapeutics) is a clinical-stage pharmaceutical company that develops novel drugs for the treatment of neurological and diseases. Its products pipeline includes LT-1001 (Naldebain), a long-acting analgesic injection that contains a prodrug of nalbuphine to treat post-operative pain; LT-3001, a novel small molecule to treat acute ischemic stroke; LT-2003, a dual-functional protein drug to treat cancer; and LT-5001, a topical drug to treat uremic pruritus. Lumosa Therapeutics provides translational research and licensing assessment services. The company collaborates with biotech and pharmaceutical companies for product licensing, development and commercialization. Lumosa Therapeutics is headquartered in Taipei city, Taipei, Taiwan.
For a complete picture of LT-1001’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
